CDK12 and cancer: They showed that the GSK3α/β inhibitors AR-A014418 and THZ531 in some cancer cells (but not including analyses of NSCLC cells) increased the PD-L1v4/PD-L1v1 mRNA ratio by decreasing the activity of CDK12 and CDK13; CDK12 knockdown promoted PD-L1 I4 poly-A signal usage; CDK13 knockdown decreased the mRNA expression of both PD-L1v1 and PD-L1v4; and a co-knockdown of CDK12 and CDK13 was required to mimic the PD-L1 transcriptional effect of THZ531.